Boston Scientific

Rosen Law Firm files securities class action against Boston Scientific, alleging false statements about U.S. Electrophysiology segment sustainability. Investors have until May 4 deadline to join.

Class action lawsuit filed against Boston Scientific alleging materially false statements about U.S. electrophysiology segment growth. Investors who purchased BSX shares July 2025-February 2026 eligible.

Securities class action alleges $BSX concealed unsustainable growth in electrophysiology segment, leading to earnings miss. Lead plaintiff deadline set for May 4, 2026.

Investors in $BSX have until May 4, 2026 to join securities class action alleging management concealed unsustainable growth and misled on segment performance.

Class action lawsuit filed against $BSX alleging material misstatements about U.S. electrophysiology segment growth. Eligible period: July 23, 2025 to February 3, 2026.

Boston Scientific ($BSX) faces securities class action lawsuit alleging false statements about U.S. Electrophysiology segment growth sustainability. Lead plaintiff deadline: May 4, 2026.

Class action lawsuit filed against $BSX alleging materially false statements about electrophysiology segment growth. Investors from July 2025-February 2026 may be eligible.

Boston Scientific faces class action lawsuit after 17.6% stock drop from weaker-than-expected electrophysiology sales; investors have until May 4, 2026 to join.

Boston Scientific faces securities fraud lawsuit over undisclosed EP segment weakness, triggering 17.6% stock decline and May 4 lead plaintiff deadline.

Boston Scientific faces class action lawsuit alleging material misstatements about U.S. electrophysiology segment. Investors from July 2025-February 2026 may have claims; May 4, 2026 deadline to apply as lead plaintiff.

Boston Scientific faces securities class action over alleged Electrophysiology segment disclosure failures. Investors must act by May 4, 2026 deadline.

Class action lawsuit filed against Boston Scientific for allegedly concealing unsustainable growth in U.S. Electrophysiology segment. Affected investors have until May 4, 2026 deadline.

Boston Scientific faces class action lawsuit alleging management concealed adverse trends in electrophysiology segment's procedure volumes and competitive pressures from July 2025 to February 2026.

Class action lawsuit filed against $BSX for allegedly misleading investors about unsustainable growth in U.S. Electrophysiology segment. Lead plaintiff deadline: May 4, 2026.

Class action lawsuit filed against $BSX alleging materially false statements regarding U.S. electrophysiology segment growth projections and undisclosed adverse trends.

Boston Scientific faces securities class action alleging false statements about Electrophysiology segment growth. Lead plaintiff deadline: May 4, 2026.

Boston Scientific shares fell 9% after Watchman FLX trial met all endpoints but disappointed investors seeking transformative clinical data to accelerate growth.

Rosen Law Firm urges $BSX investors to join securities lawsuit alleging false statements about U.S. Electrophysiology segment sustainability. Lead plaintiff deadline: May 4, 2026.

Class action lawsuit alleges Boston Scientific made false statements about U.S. electrophysiology segment sustainability, citing undisclosed competitive pressures and regulatory headwinds affecting procedure volumes.

Robbins Geller launches class action lawsuit against $SNOW, alleging securities fraud over false product efficiency claims and material business disclosures between June 2023 and February 2024.